Wisconsin

From 2007.igem.org

(Difference between revisions)
Line 1: Line 1:
-
{| border="0" cellspacing="8px" cellpadding="15" width="100%"
+
{| border="0" cellspacing="6px" cellpadding="10" width="100%"
|-
|-
|[[Wisconsin|Home]]
|[[Wisconsin|Home]]
Line 10: Line 10:
<center>[[Image:IGEM_soft_logo.jpg]]</center>
<center>[[Image:IGEM_soft_logo.jpg]]</center>
-
 
-
==Widgeteers==
 
-
Junior Widgeteer
 
-
*Nathan Klapoetke
 
-
*Sean McMaster
 
-
*David Peterson
 
-
 
-
 
-
Chief Widgeteer
 
-
*Aseem Ansari
 
-
*Clay Carlson
 
-
*Franco Cerrina
 
-
*Mary Ozers
 
-
*Doug Weibel
 
-
 
-
 
-
==[[Wisconsin/Project Description|Project ATF]]==
 
-
Doxrubicin is a widely used drug to treat cancer. However one main limitation of its use is cardiotoxicity. Accumulated dose of doxrubicin can cause oxidative stress to cardiomyocytes and trigger apoptosis. Our goal is to up-regulate bcl-2 (a pro-survival protein) and prevent cells from dying under mild stress. We have designed an inducible artificial transcription factor (ATF) that binds to bcl-2 promoter. Currently we are studying cell fate regulation using ATF in mouse fibroblast cells.
 
-
 
-
==Protocol==
 
-
 
-
===Cloning===
 
-
*[[Wisconsin/Protocol:Digestion|Digestion]]
 
-
*[[Wisconsin/Protocol:Ligation|Ligation]]
 
-
*[[Wisconsin/Protocol:Miniprep|Miniprep]]
 
-
*[[Wisconsin/Protocol:Primer|Primer Design]]
 
-
*[[Wisconsin/Protocol:Transformation|Transformation]]
 
-
*[[Wisconsin/Protocol:Cell Culture|Cell Culture]]
 
-
 
-
===Instrument===
 
-
*[[Wisconsin/Protocol:Agarose Gel|Gel Electrophoresis]]
 
-
*[[Wisconsin/Protocol:NanoDrop|NanoDrop]]
 
-
*[[Wisconsin/Protocol:PCR|PCR and PCR Purification]]
 

Revision as of 16:02, 26 October 2007

Home ATF Project BCL-2 Project Protocols Acknowledgements About Us
IGEM soft logo.jpg